This is the library for the enduring materials from the Targets in Cancer IO: A Deep Dive in Enhanced CTLA-4 blockade webinar that was conducted on October 5, 2022.Moderators:
Faculty:
Targets for Cancer IO: A Deep Dive Series 2 is supported, in part, by educational grants from Genmab, US, Inc. Iovance Biotherapeutics, and Merck & Co., Inc. (as of 7/26/2022).Interested in supporting this program? The SITC Development team would love to work with you. Contact Development@sitcancer.org for more information on how your organization's support can help advance cancer immunotherapy and make "cure" a reality.
Meeting: 2022 Targets in Cancer IO: A Deep Dive in Enhanced CTLA-4 blockade; Moderators: James P. Allison, PhD, FAIO – The University of Texas MD Anderson Cancer Center, Alan J. Korman, PhD, FAIO – Vir Biotechnology; Speakers: Aurelien Marabelle, MD, PhD – Gustave Roussy, Simon J. Dovedi, PhD – AstraZeneca, Nick Wilson, PhD – Bristol Myers Squibb, Dhan Chand, PhD – Agenus; Date: October 5, 202201:55:37